Questcor Pharmaceuticals (NASDAQ:QCOR) EVP David Jeffrey Medeiros sold 2,292 shares of the stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $77.15, for a total transaction of $176,827.80. Following the completion of the sale, the executive vice president now directly owns 120,039 shares in the company, valued at approximately $9,261,009. Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) shares after opening at $81.27 moved to $83.89 on last trade day and at the end of the day closed at $82.30. Company price to sales ratio in past twelve months was calculated as 6.24 and price to cash ratio as 20.35. Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) showed a positive weekly performance of 4.89%.
Arena Pharmaceuticals (NASDAQ:ARNA) Director Harry F. Hixson, Jr. sold 36,900 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, April 22nd. The stock was sold at an average price of $6.31, for a total value of $232,839.00. Following the transaction, the director now directly owns 82,876 shares in the company, valued at approximately $522,948. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares advanced 0.16% in last trading session and ended the day on $6.17. ARNA return on equity ratio is recorded as -19.10% and its return on assets is -6.80%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) yearly performance is -21.70%.
Acceleron Pharma (NASDAQ:XLRN) SVP Steven D. Ertel sold 2,500 shares of the company’s stock on the open market in a transaction dated Tuesday, April 22nd. The stock was sold at an average price of $35.87, for a total value of $89,675.00. Following the completion of the transaction, the senior vice president now directly owns 27,656 shares of the company’s stock, valued at approximately $992,021. Acceleron Pharma Inc. (NASDAQ:XLRN) shares moved down -4.70% in last trading session and was closed at $31.85, while trading in range of $30.00 – $35.19. Acceleron Pharma Inc. (NASDAQ:XLRN) year to date (YTD) performance is -19.57%.
XenoPort, Inc. (NASDAQ:XNPT) Director Paul L Berns sell 2,500 shares in a transaction dated Thursday, April 24th. The stock was sold at an average price of $4.30 per share, for a total transaction of $10,750.00. XenoPort, Inc. (NASDAQ:XNPT) weekly performance is 7.18%. On last trading day company shares ended up $4.48. XenoPort, Inc. (NASDAQ:XNPT) distance from 50-day simple moving average (SMA50) is -18.46%. Analysts mean target price for the company is $7.80.
Leave a Reply